Latest Posts
Cook Medical Appoints John A. Kaufman as Chief Medical Officer
Cook Medical announced the appointment of John A. Kaufman, MD, MS, as Chief Medical Officer (CMO), effective July 2023. Currently, Dr. Kaufman is the inaugural Chair of the Dotter Department of Interventional Radiology, Director of the Dotter Interventional Institute, and Frederick S. Keller Professor of Interventional Radiology at the Oregon
Merit Medical’s EmboCube Embolization Gelatin to Be Studied to Control Bleeding or Hemorrhage
Merit Medical Systems, Inc. announced the enrollment of the first patient in the company’s prospective, observational study of EmboCube embolization gelatin to control bleeding or hemorrhage. The EmboCube Embolization Gelatin study is designed to enroll 100 patients across multiple centers in Australia and France. The company advised that EmboCube is
Vesalio’s NeVa Thrombectomy Device First-Pass Rates Evaluated in Published Study
Vesalio announced that data on the use of the company’s NeVa thrombectomy device were published by Arsida Bajrami, MD, et al in Interventional Neuroradiology. The company stated that the NeVa platform is designed to consistently achieve first-pass recanalization in stroke by effectively removing all types of neurovascular clots from a
Starting a vein practice? Start here!
Quality Training All Treatment Modalities You, your staff, your patients in the comfort of your own office. Real hands on training! Our on-site consultant Joyce Vining RVT, LPN 25 years experience treating vein disease. Venous Ultrasound | Endovenous Ablation | Phlebectomy | Sclerotherapy Need Office Forms, Photos, and Patient Education?
FDA Breakthrough Device designation
Cook Medical announced that its Thoraco+ endovascular system has received Breakthrough Device designation from the FDA. The company describes Thoraco+ as a next- generation, off-the-shelf device in the Zenith platform, indicated for patients with thoracoabdominal aortic aneurysms (Crawford classification I-IV). It has four side branches for the celiac, superior mesenteric,
Alucent’s natural vascular scaffolding to be evaluated in ACTIVATE II FIH trial
Alucent Biomedical Inc. announced that it has enrolled the first patient in ACTIVATE II, an Australia-based first-in-human clinical trial to evaluate the safety and efficacy of AlucentNVS, the company’s natural vascular scaffolding device. According to the company, the ACTIVATE II trial will enroll up to 50 patients at up to